Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) on February 28 and set a price target of $65.00. The company’s shares closed last Wednesday at $46.06.
According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.8% and a 38.8% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Twist Bioscience, and Guardant Health.
Castle Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $61.75, which is a 32.3% upside from current levels. In a report issued on February 28, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $60.00 price target.
Based on Castle Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $23.48 million and GAAP net loss of $11.79 million. In comparison, last year the company earned revenue of $15.22 million and had a GAAP net loss of $4.59 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Read More on CSTL:
- Bicycle Therapeutics (BCYC) Gets a Buy Rating from Leerink Partners
- Robert W. Baird Maintains Their Hold Rating on Mayville Engineering Company (MEC)
- Leerink Partners Thinks Turning Point Therapeutics’ Stock is Going to Recover
- Arvinas Holding Company (ARVN) Gets a Buy Rating from Leerink Partners
- Leerink Partners Keeps a Hold Rating on Allakos (ALLK)